SOURCE: Paragon Financial Limited

Paragon Financial Limited

October 19, 2012 08:20 ET

FDA Considering Faster Pathway for Treatments of Deadly or Debilitating Diseases

The Paragon Report Provides Stock Research on InterMune and ACADIA Pharmaceuticals

NEW YORK, NY--(Marketwire - Oct 19, 2012) - The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on InterMune, Inc. (NASDAQ: ITMN) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD).

Access to the full company reports can be found at:

www.ParagonReport.com/ITMN

www.ParagonReport.com/ACAD

Under the new pathway the FDA would allow developers of such drugs to conduct smaller, faster clinical trials, and provide a "special medical use" label which would allow doctors to administer drugs to patients with critical need. Hamburg has said that the FDA needs to take into account the needs of people with deadly or debilitating diseases that may be willing to take on the risks of unproven drugs.

"A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good," said Pew Health Group's Allan Coukell, deputy director of medical programs. "It would be good for developers, for companies and it would be good for public health."

Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. The company earlier this month reported Health Canada has approved Esbriet for the treatment of mild to moderate idiopathic pulmonary fibrosis. Shares of InterMune have gained over 13 percent in the last week.

ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

http://www.paragonreport.com/disclaimer